Hepatitis B virus resistance to nucleos(t)ide analogue therapy: WHO consultation on questions, challenges, and a roadmap for the field

IF 20.4 1区生物学 Q1 INFECTIOUS DISEASES

Lancet Microbe Pub Date : 2025-08-01 DOI:10.1016/j.lanmic.2025.101076

Sheila F Lumley PhD MRCP , Jolynne Mokaya PhD , Tongai G Maponga PhD , Prof Anna Kramvis PhD , Prof Geoffrey Dusheiko FRCP , Prof William Irving PhD , Marion Delphin PhD , Khadija Said Mohammed MSc , Louise O Downs FRCPath , Elizabeth Waddilove MSc , Motswedi Anderson PhD , Prof Collins Iwuji MBBS MD , Nokukhanya Msomi MBChB PhD , Ponsiano Ocama MD PhD , Prof Saeed Hamid FRCP , Danjuma Adda MPH , Rachel Halford , Kenneth Kabagambe MPH , Kimberley S M Benschop PhD , Seth Inzaule PhD , Prof Philippa C Matthews PhD FRCPath

{"title":"Hepatitis B virus resistance to nucleos(t)ide analogue therapy: WHO consultation on questions, challenges, and a roadmap for the field","authors":"Sheila F Lumley PhD MRCP , Jolynne Mokaya PhD , Tongai G Maponga PhD , Prof Anna Kramvis PhD , Prof Geoffrey Dusheiko FRCP , Prof William Irving PhD , Marion Delphin PhD , Khadija Said Mohammed MSc , Louise O Downs FRCPath , Elizabeth Waddilove MSc , Motswedi Anderson PhD , Prof Collins Iwuji MBBS MD , Nokukhanya Msomi MBChB PhD , Ponsiano Ocama MD PhD , Prof Saeed Hamid FRCP , Danjuma Adda MPH , Rachel Halford , Kenneth Kabagambe MPH , Kimberley S M Benschop PhD , Seth Inzaule PhD , Prof Philippa C Matthews PhD FRCPath","doi":"10.1016/j.lanmic.2025.101076","DOIUrl":null,"url":null,"abstract":"<div><div>In this Review, we summarise outputs from a multidisciplinary consultation convened by WHO between July 11 and 13, 2023, to discuss hepatitis B virus (HBV) drug resistance (HBVDR). Treatment of chronic HBV infection with highly effective nucleos(t)ide analogue agents, tenofovir and entecavir, is a crucial intervention that supports the global goal of elimination of HBV infection as a public health threat. The risk of HBVDR as a threat to treatment outcomes is currently considered low from a public health perspective; however, drug resistance can influence individual outcomes, particularly among those who are treatment-experienced. We highlight the need to develop appropriate prevention, monitoring, and surveillance approaches for HBVDR, to support investment in the global scale-up of HBV diagnosis and treatment. Recommendations for the HBVDR field will ultimately be incorporated into a WHO integrated Global Action Plan for drug-resistant HIV, viral hepatitis, and priority sexually transmitted infections.</div></div>","PeriodicalId":46633,"journal":{"name":"Lancet Microbe","volume":"6 8","pages":"Article 101076"},"PeriodicalIF":20.4000,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Lancet Microbe","FirstCategoryId":"99","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2666524725000047","RegionNum":1,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}

引用次数: 0

Abstract

In this Review, we summarise outputs from a multidisciplinary consultation convened by WHO between July 11 and 13, 2023, to discuss hepatitis B virus (HBV) drug resistance (HBVDR). Treatment of chronic HBV infection with highly effective nucleos(t)ide analogue agents, tenofovir and entecavir, is a crucial intervention that supports the global goal of elimination of HBV infection as a public health threat. The risk of HBVDR as a threat to treatment outcomes is currently considered low from a public health perspective; however, drug resistance can influence individual outcomes, particularly among those who are treatment-experienced. We highlight the need to develop appropriate prevention, monitoring, and surveillance approaches for HBVDR, to support investment in the global scale-up of HBV diagnosis and treatment. Recommendations for the HBVDR field will ultimately be incorporated into a WHO integrated Global Action Plan for drug-resistant HIV, viral hepatitis, and priority sexually transmitted infections.

查看原文本刊更多论文

乙型肝炎病毒对核苷类似物治疗的耐药性：世卫组织就该领域的问题、挑战和路线图进行磋商。

在本综述中，我们总结了世卫组织于2023年7月11日至13日召开的讨论乙型肝炎病毒（HBV）耐药性（HBVDR）的多学科磋商的成果。用高效的核苷(t)类似物替诺福韦和恩替卡韦治疗慢性HBV感染是支持消除作为公共卫生威胁的HBV感染这一全球目标的关键干预措施。从公共卫生角度来看，HBVDR对治疗结果构成威胁的风险目前被认为很低；然而，耐药性会影响个人的结果，特别是那些接受过治疗的人。我们强调需要制定适当的乙型肝炎病毒预防、监测和监测方法，以支持在全球扩大乙型肝炎病毒诊断和治疗方面的投资。HBVDR领域的建议最终将被纳入世卫组织针对耐药艾滋病毒、病毒性肝炎和重点性传播感染的综合全球行动计划。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Lancet Microbe Multiple-

CiteScore

27.20

自引率

0.80%

发文量

278

审稿时长

6 weeks

期刊介绍： The Lancet Microbe is a gold open access journal committed to publishing content relevant to clinical microbiologists worldwide, with a focus on studies that advance clinical understanding, challenge the status quo, and advocate change in health policy.